Efficacy and safety of switching from thrice daily glinide or alpha-GI to twice daily mitiglinide/voglibose combined drug in type 2 diabetes.

Trial Profile

Efficacy and safety of switching from thrice daily glinide or alpha-GI to twice daily mitiglinide/voglibose combined drug in type 2 diabetes.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2014

At a glance

  • Drugs Mitiglinide/voglibose (Primary) ; Alpha-glucosidase inhibitors; Meglitinide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top